The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLMC 2020 | The future role of MRD measurement in CLL
Jenifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the current and future role of minimal residual disease (MRD) measurement in chronic lymphocytic leukemia (CLL). Dr/Prof Woyach highlights the approval of the ClonoSEQ sequencing method which has superior sensitivity to MRD in CLL patients compared with previous methods, and the potential of retrospective and prospective studies to determine whether CLL treatment duration could be based on MRD in the future. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consulting/advisory boards: Janssen, Pharmacyclics, Abbvie, AstraZeneca, Arqule
